EPZ005687

Biochemical enzyme assays

Compound was incubated for 30 mins with 40 μL per well of 5 nM PRC2 (final assay concentration in 50 μL was 4 nM) in 1× assay buffer (20 mM Bicine [pH 7.6], 0.002% Tween-20, 0.005% Bovine Skin Gelatin and 0.5 mM DTT). 10 μL per well of substrate mix comprising assay buffer 3H-SAM, unlabeled SAM, and peptide representing histone H3 residues 21-44 containing C-terminal biotin (appended to a C-terminal amide-capped lysine) were added to initiate the reaction (both substrates were present in the final reaction mixture at their respective Km values, an assay format referred to as “balanced conditions”). The final concentrations of substrates and methylation state of the substrate peptide were indicated for each enzyme. Reactions were incubated for 90 mins at room temperature and quenched with 10 μL per well of 600 μM unlabeled SAM. The mixtures were then transferred to a 384-well flashplate and washed after 30 mins.

Cell lines

OCI-LY19, WSU-DLCL2 and Pfeiffer cells

Preparation method

The solubility of this compound in DMSO is limited. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20 °C for several months.

Reaction Conditions

0.011 ~ 8.3 μM; 11 days

Applications

EPZ005687 significantly inhibited the proliferation of WSU-DLCL2 and Pfeiffer cells, with minimal effects on the proliferation of OCI-LY19 cells.

Animal models

Osteoarthritis (OA) mouse model

Dosage form

5.6 μM, 50 μL; intra-articular injection; at 7th, 15th and 30th days

Applications

Intra-articular injection of EPZ005687 delayed OA development in mice.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

[1]. Knutson SK, Wigle TJ, Warholic NM, Sneeringer CJ, Allain CJ, Klaus CR, Sacks JD, Raimondi A, Majer CR, Song J, Scott MP, Jin L, Smith JJ, Olhava EJ, Chesworth R, Moyer MP, Richon VM, Copeland RA, Keilhack H, Pollock RM, Kuntz KW. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol. 2012 Nov;8(11):890-6.

[2]. Chen L, Wu Y, Wu Y, Wang Y, Sun L, Li F. The inhibition of EZH2 ameliorates osteoarthritis development through the Wnt/β-catenin pathway. Sci Rep. 2016 Aug 19;6:29176.